Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
Schmieder, Roberta, Puehler, Florian, Neuhaus, Roland, Kissel, Maria, Adjei, Alex A, Miner, Jeffrey N, Mumberg, Dominik, Ziegelbauer, Karl, Scholz, ArneVolume:
15
Language:
english
Journal:
Neoplasia
DOI:
10.1593/neo.13812
Date:
October, 2013
File:
PDF, 1.76 MB
english, 2013